Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | BACE1 | P56817 | 7/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.33 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.33 |
| ▸ | CTSD | P07339 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.33 |
| ▸ | MPI | P34949 | 1/20 | 0.33 |
| ▸ | REN | P00797 | 3/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23578108 | 0.85 | ALDH1A1 (0.40) | ALDH1A1PTGDR2GAA | |
| SCHEMBL2486662 | 0.83 | PGR (0.37) | ALDH1A1AURKAAURKBTDP1MPI | |
| SCHEMBL14401726 | 0.83 | BACE1 (0.38) | ALDH1A1BACE1PTGDR2CTSDTDP1 | |
| SCHEMBL14401638 | 0.83 | PTGDR2 (0.40) | ALDH1A1BACE1PTGDR2CTSDTDP1 | |
| SCHEMBL2487312 | 0.82 | BACE1 (0.33) | BACE1AURKAAURKBCYP2D6CYP2C9 | |
| SCHEMBL6451576 | 0.81 | MEN1 (0.39) | ALDH1A1AURKAAURKBTDP1GAA | |
| SCHEMBL4143673 | 0.80 | DUT (0.35) | AURKAAURKB | |
| SCHEMBL2486094 | 0.80 | AURKA (0.44) | ALDH1A1BACE1AURKAAURKBTDP1 | |
| SCHEMBL6450666 | 0.79 | SCN9A (0.40) | — | |
| SCHEMBL13341347 | 0.79 | ALDH1A1 (0.35) | ALDH1A1BACE1AURKAAURKBTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | F. HOFFMANN-LA ROCHE AG (CH) | 2009-06-04 | — | — | US | disclosed |
| EP-1966213-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F.HOFFMANN-LA ROCHE AG (CH) | 2008-09-10 | — | — | EP | disclosed |
| WO-2007068465-A1 | TRICYCLIC LACTAM DERIVATIVES, THEIR MANUFACTURE AND USE AS PHARMACEUTICAL AGENTS | F. HOFFMANN-LA ROCHE AG (CH) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143375-A1 | Tricyclic Lactam Derivatives, Their Manufacture and Use as Pharmaceutical Agents | AAAS, CYP3A5, BRCA1 | ALDH1A1 898/4885BACE1 82/4885PTGDR2 2648/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.